Clinical outcomes of genomically guided trametinib monotherapy across cancer types: results from the IMPRESS-Norway trial.

Slørdahl KS, Puco K, Falk RS, Dyvik I, Brabrand S, Niehusmann P, Steinskog ESS, Blix ES, Flobak Å, Oppedal IA, Meltzer S, Torkildsen CF, Blakstad H, Lindemann K, Smeland S, Amundsen A, Taskén K, Helland Å, InPred Consortium.

Open source

DOI: 10.2340/1651-226x.2026.45086
Published: 2026-02-10
Container: Acta Oncol
Publisher: Not recorded
Open access: yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
supportingDirectory of Open Access Journals: A matching record was returned by DOAJ. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.2340/1651-226x.2026.45086,
  title = {Clinical outcomes of genomically guided trametinib monotherapy across cancer types: results from the IMPRESS-Norway trial.},
  author = {Slørdahl KS and  Puco K and  Falk RS and  Dyvik I and  Brabrand S and  Niehusmann P and  Steinskog ESS and  Blix ES and  Flobak Å and  Oppedal IA and  Meltzer S and  Torkildsen CF and  Blakstad H and  Lindemann K and  Smeland S and  Amundsen A and  Taskén K and  Helland Å and  InPred Consortium.},
  year = {2026},
  journal = {Acta Oncol},
  doi = {10.2340/1651-226x.2026.45086},
  url = {https://doi.org/10.2340/1651-226x.2026.45086}
}

RIS

TY  - JOUR
TI  - Clinical outcomes of genomically guided trametinib monotherapy across cancer types: results from the IMPRESS-Norway trial.
AU  - Slørdahl KS
AU  -  Puco K
AU  -  Falk RS
AU  -  Dyvik I
AU  -  Brabrand S
AU  -  Niehusmann P
AU  -  Steinskog ESS
AU  -  Blix ES
AU  -  Flobak Å
AU  -  Oppedal IA
AU  -  Meltzer S
AU  -  Torkildsen CF
AU  -  Blakstad H
AU  -  Lindemann K
AU  -  Smeland S
AU  -  Amundsen A
AU  -  Taskén K
AU  -  Helland Å
AU  -  InPred Consortium.
PY  - 2026
JO  - Acta Oncol
DO  - 10.2340/1651-226x.2026.45086
UR  - https://doi.org/10.2340/1651-226x.2026.45086
ER  -

APA

KS, S., K, P., RS, F., I, D., S, B., P, N., ESS, S., ES, B., Å, F., IA, O., S, M., CF, T., H, B., K, L., S, S., A, A., K, T., Å, H., & Consortium., I. (2026). Clinical outcomes of genomically guided trametinib monotherapy across cancer types: results from the IMPRESS-Norway trial.. Acta Oncol. https://doi.org/10.2340/1651-226x.2026.45086

Source records

europe-pmc · retrieved 2026-09-27T02:24:13.616Z
doaj · retrieved 2026-09-27T02:24:13.614Z